153 related articles for article (PubMed ID: 38184132)
1. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis.
Kaddoura R; Madurasinghe V; Chapra A; Abushanab D; Al-Badriyeh D; Patel A
Curr Probl Cardiol; 2024 Mar; 49(3):102376. PubMed ID: 38184132
[TBL] [Abstract][Full Text] [Related]
2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
4. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction.
Lund LH; Benson L; Dahlström U; Edner M; Friberg L
JAMA; 2014 Nov; 312(19):2008-18. PubMed ID: 25399276
[TBL] [Abstract][Full Text] [Related]
5. Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction.
Farasat SM; Bolger DT; Shetty V; Menachery EP; Gerstenblith G; Kasper EK; Najjar SS
Am J Cardiol; 2010 Jan; 105(2):229-34. PubMed ID: 20102924
[TBL] [Abstract][Full Text] [Related]
6. The impact of right ventricular dysfunction on the effectiveness of beta-blockers in heart failure with preserved ejection fraction.
Harada D; Asanoi H; Noto T; Takagawa J
J Cardiol; 2020 Oct; 76(4):325-334. PubMed ID: 32475652
[TBL] [Abstract][Full Text] [Related]
7. Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes.
Patel K; Fonarow GC; Ekundayo OJ; Aban IB; Kilgore ML; Love TE; Kitzman DW; Gheorghiade M; Allman RM; Ahmed A
Int J Cardiol; 2014 May; 173(3):393-401. PubMed ID: 24703206
[TBL] [Abstract][Full Text] [Related]
8. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis.
Bavishi C; Chatterjee S; Ather S; Patel D; Messerli FH
Heart Fail Rev; 2015 Mar; 20(2):193-201. PubMed ID: 25034701
[TBL] [Abstract][Full Text] [Related]
9. Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate.
Lam PH; Gupta N; Dooley DJ; Singh S; Deedwania P; Zile MR; Bhatt DL; Morgan CJ; Pitt B; Fonarow GC; Ahmed A
Am J Med; 2018 Dec; 131(12):1473-1481. PubMed ID: 30076815
[TBL] [Abstract][Full Text] [Related]
10. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study.
Gu J; Fan YQ; Bian L; Zhang HL; Xu ZJ; Zhang Y; Chen QZ; Yin ZF; Xie YS; Wang CQ
Eur J Prev Cardiol; 2016 Sep; 23(13):1421-8. PubMed ID: 26915580
[TBL] [Abstract][Full Text] [Related]
11. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
[TBL] [Abstract][Full Text] [Related]
12. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
[TBL] [Abstract][Full Text] [Related]
13. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial.
Silverman DN; Plante TB; Infeld M; Callas PW; Juraschek SP; Dougherty GB; Meyer M
JAMA Netw Open; 2019 Dec; 2(12):e1916598. PubMed ID: 31800067
[TBL] [Abstract][Full Text] [Related]
14. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis.
Liu F; Chen Y; Feng X; Teng Z; Yuan Y; Bin J
PLoS One; 2014; 9(3):e90555. PubMed ID: 24599093
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
DE Vecchis R; Ariano C
Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Heart Rate and Beta-Blocker Use in Sinus Rhythm in Patients with Heart Failure and Preserved Ejection Fraction.
Li S; Li X
High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):405-411. PubMed ID: 31625118
[TBL] [Abstract][Full Text] [Related]
17. The effect of beta-blockers on mortality in heart failure with preserved ejection fraction: A meta-analysis of observational cohort and randomized controlled studies.
Fukuta H; Goto T; Wakami K; Ohte N
Int J Cardiol; 2017 Feb; 228():4-10. PubMed ID: 27863360
[TBL] [Abstract][Full Text] [Related]
18. Association between the beta-blockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
Wu M; Ni D; Huang LL; Qiu S
Clin Cardiol; 2023 Aug; 46(8):845-852. PubMed ID: 37272188
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
[TBL] [Abstract][Full Text] [Related]
20. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
